News & Updates
Filter by Specialty:
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
In the treatment of patients with drug-resistant epilepsy associated with tuberous sclerosis complex, the antiseizure effect of cannabidiol occurs within 6–10 days, according to the results of a phase III trial. Adverse events also emerge during the first 2 weeks of the titration period, and majority of these are resolved during the 16-week treatment period.
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
28 Mar 2022
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
Patients with childhood-onset chronic rheumatic disease (CRD) do not perform as well as their peers on grade 12 standardized testing, independent of sociodemographic and mental health comorbidities, reports a population-based retrospective cohort study.
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
27 Mar 2022
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.
